Top 35 Companies Leading the Global Alpha Emitters Market
Bayer AG
Novartis AG
Actinium Pharmaceuticals, Inc.
Fusion Pharmaceuticals Inc. (AstraZeneca)
Alpha Tau Medical Ltd.
Telix Pharmaceuticals Limited
IBA Radiopharma Solutions
Siemens Healthineers AG
Lantheus Holdings, Inc.
Orano Med
PanTera GmbH
RadioMedix, Inc.
Triad Isotopes, Inc.
Advanced Accelerator Applications (Novartis)
AstraZeneca plc
Eli Lilly and Company
Bristol-Myers Squibb Company
Alpha Tau Medical Ltd.
Headquarters: Jerusalem, Israel
Alpha Tau Medical develops Alpha DaRT, a diffusing alpha-emitter radiation therapy device implanted directly into solid tumors, and received FDA Investigational Device Exemption in 2025 to evaluate the technology in recurrent glioblastoma. The company's locally implanted alpha source approach represents a differentiated technology platform within the broader alpha emitters market. Expanding clinical trial activity across multiple solid tumor types reinforces Alpha Tau Medical's position in the global alpha emitters market.